Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Cancer Vaccines01:30

Cancer Vaccines

854
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
854
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

17.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Conjugated Proteins02:50

Conjugated Proteins

25.0K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
25.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Vaccinations01:51

Vaccinations

50.5K
Overview
50.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

mRNA-based influenza vaccine expands the B cell response breadth in humans.

Nature immunology·2026
Same author

Hemagglutination inhibition and alternate serologic responses following Influenza A(H3N2) virus infection.

medRxiv : the preprint server for health sciences·2026
Same author

Local B cell immunity and durable memory after live-attenuated influenza intranasal vaccination of humans.

Science translational medicine·2026
Same author

B lymphocyte protein factories produced by hematopoietic stem cell gene editing.

Science (New York, N.Y.)·2026
Same author

Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies.

mBio·2026
Same author

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.

Nature microbiology·2026
Same journal

Daily briefing: 'Cyborg' cockroaches breathe underwater with printed suit.

Nature·2026
Same journal

China boosts prestigious grants for young scientists - will it ease competition?

Nature·2026
Same journal

Incoming US science academy chief vows to 'double down' on research.

Nature·2026
Same journal

Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemization.

Nature·2026
Same journal

Electrodeposited self-assembled molecules for perovskite photovoltaics.

Nature·2026
Same journal

Neutrino's nursery found: the 'Shadow Blaster'.

Nature·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Dec 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Vacunas contra el SARS-CoV-2 en desarrollo

Florian Krammer1

  • 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.

Nature
|September 23, 2020
PubMed
Resumen
Este resumen es generado por máquina.

El desarrollo de vacunas contra el síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) está progresando rápidamente. Los primeros datos de ensayos sugieren que las vacunas seguras y efectivas contra la enfermedad por coronavirus 2019 (COVID-19) podrían estar disponibles pronto.

Más Videos Relacionados

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.3K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.0K

Videos de Experimentos Relacionados

Last Updated: Dec 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.3K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.0K

Área de la Ciencia:

  • Virología
  • Inmunología
  • Vacunas y vacunas

Sus antecedentes:

  • El surgimiento del síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) a finales de 2019 desencadenó la pandemia de la enfermedad por coronavirus 2019 (COVID-19).
  • Existe una necesidad crítica de vacunas para mitigar el impacto global de COVID-19 en la salud pública, las economías y las sociedades.

Objetivo del estudio:

  • Proporcionar una revisión exhaustiva del desarrollo en curso de vacunas dirigidas al SARS-CoV-2.
  • Evaluar la velocidad y el progreso sin precedentes de los esfuerzos de desarrollo de vacunas.

Principales métodos:

  • Revisión de las iniciativas de desarrollo de vacunas iniciadas tras la publicación de la secuencia genética del SARS-CoV-2 a principios de enero de 2020.
  • Análisis de los datos de los ensayos clínicos en curso, incluidas las fases I, II y III.

Principales resultados:

  • Más de 180 candidatos a vacunas contra el SARS-CoV-2 se encuentran actualmente en varias etapas de desarrollo.
  • Los datos de los ensayos de fase I y II están disponibles para numerosos candidatos, y muchos avanzan a los ensayos de fase III.
  • El rápido ritmo de desarrollo ha sido sin precedentes, con los ensayos de fase I que comenzarán en marzo de 2020.

Conclusiones:

  • Los datos actuales indican una fuerte posibilidad de que las vacunas efectivas y seguras contra el SARS-CoV-2 estén disponibles dentro de unos meses.
  • La línea de tiempo acelerada de desarrollo de vacunas ofrece esperanza para controlar la pandemia de COVID-19.